Potential role of interleukin-10-secreting regulatory T cells in allergy and asthma

Nature Reviews Immunology

Volumn 5, Issue 4, 2005, Pages 271-283

  Hawrylowicz, C M ^a   O'Garra, A ^b  

^a GUY S HOSPITAL   (United Kingdom)

^b NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HISTAMINE; INTERLEUKIN 10; LEUKOTRIENE;

ALLERGIC DISEASE; ALLERGIC RHINITIS; ALLERGY; ASTHMA; BLOOD VESSEL PERMEABILITY; CONJUNCTIVITIS; CYTOKINE RELEASE; FOOD ALLERGY; HISTAMINE RELEASE; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; LYMPHOCYTE FUNCTION; LYMPHOCYTE SUBPOPULATION; MOUSE; MUCUS SECRETION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SMOOTH MUSCLE CONTRACTION; TH2 CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ASTHMA; HUMANS; HYPERSENSITIVITY; IMMUNOTHERAPY; INTERLEUKIN-10; T-LYMPHOCYTE SUBSETS; TH2 CELLS;

EID: 17144405680     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri1589     Document Type: Review

References (188)

1. Kay, A. B. Allergy and allergic diseases. First of two parts. N. Engl. J. Med. 344, 30-37 (2001).
2. Holgate, S. T. & Broide, D. New targets for allergic rhinitis - a disease of civilization. Nature Rev. Drug Discov. 2, 902-914 (2003).
3. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivis, and atopic eczema: ISAAC. Lancet 351, 1225-1232 (1998).
4. Burney, P. et al. The distribution of total and specific serum IgE in the European Community Respiratory Health Survey. J. Allergy Clin. Immunol. 99, 314-322 (1997).
5. H2 cytokines in allergic disease. Br. Med. Bull. 56, 956-968 (2000).
6. Cookson, W. & Moffatt, M. Making sense of asthma genes. N. Engl. J. Med. 351, 1794-1796 (2004).
7. Wills-Karp, M., Santeliz, J. & Karp, C. L. The germless theory of allergic disease: revisiting the hygiene hypothesis. Nature Rev. Immunol. 1, 69-75 (2001).
8. H2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7, 145-173 (1989).
9. Romagnani, S. Regulation of the development of type 2 T-helper cells in allergy. Curr. Opin. Immunol. 6, 838-846 (1994).
10. H2-cytokine-mRNA-positive T cells in the lungs of patients with allergic asthma.
11. Bentley, A. M. et al. Increases in activated T lymphocytes, eosinophis, and cytokine mRNA expression for interleukin-5 and granulocyte/macrophage colony-stimulating factor in bronchial biopsies after allergen inhalation challenge in atopic asthmatics. Am. J. Respir. Cell Mol. Biol. 8, 35-42 (1993).
12. Lloyd, C. M., Gonzalo, J. A., Coyle, A. J. & Gutierrez-Ramos, J. C. Mouse models of allergic airway disease. Adv. Immunol. 77, 263-295 (2001).
13. Barnes, P. J. Current therapies for asthma. Promise and limitations. Chest 111, 17S-26S (1997).
14. Maloy, K. J. & Powrie, F. Regulatory T cells in the control of immune pathology. Nature Immunol. 2, 816-822 (2001).
15. + regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22, 531-562 (2004).
16. O'Garra, A. & Vieira, P. Regulatory T cells and mechanisms of immune system control. Nature Med. 10, 801-805 (2004).
17. + suppressor T cells: more questions than answers. Nature Rev. Immunol. 2, 389-400 (2004). References 14-17 are key reviews that describe naturally occurring and antigen-driven regulatory T cells, and they refer to the important original papers in this field.
18. + T cells regulate the expansion of peripheral CD4 T cells through the production of IL-10. J. Immunol. 166, 3008-3018 (2001).
19. R cells suppress innate immune pathology through cytokine-dependent mechanisms. J. Exp. Med. 197, 111-119 (2003).
20. + regulatory T cells induced by an agonist self-peptide. Nature Immunol. 2, 301-306 (2001).
21. Apostolou, I. & Von Boehmer, H. In vivo instruction of suppressor commitment in naive T cells. J. Exp. Med. 199, 1401-1408 (2004).
22. +high regulatory T cell function. J. Immunol. 169, 6210-6217 (2002).
23. + regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol. Res. 182, 18-32 (2001).
24. + regulatory cells that control intestinal inflammation. J. Exp. Med. 192, 295-302 (2000).
25. + regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med. 192, 303-310 (2000).
26. + regulatory T cells through GITR breaks immunological self-tolerance. Nature Immunol. 3, 135-142 (2002).
27. + immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 16, 311-323 (2002).
28. + T cells through TGF-β-TGF-β receptor interactions in type 1 diabetes. Proc. Natl Acad. Sci. USA 100, 10876-10883 (2003).
29. Asseman, C., Mauze, S., Leach, M. W., Coffman, R. L. & Powrie, F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J. Exp. Med. 190, 995-1004 (1999).
30. + regulatory T cells control Leishmania major persistence and immunity. Nature 420, 502-507 (2002).
31. + T cells. J. Autoimmun. 16, 115-123 (2001).
32. Hori, S., Nomura, T. & Sakaguchi, S. Control of regulatory T cell development by the transcription factor Foxp3. Science 299, 1057-1061 (2003).
33. + T regulatory cells. Nature Immunol. 4, 337-342 (2003).
34. Reg cells.
35. Ramsdell, F. Foxp3 and natural regulatory T cells: key to a cell lineage? Immunity 19, 165-168 (2003).
36. + regulatory T cells. Int. Immunol. 16, 1643-1656 (2004).
37. + regulatory T cells by TGF-β induction of transcription factor Foxp3. J. Exp. Med. 198, 1875-1886 (2003).
38. + T cells. J. Clin. Invest. 112, 1437-1443 (2003).
39. + T cells. Immunity 1, 553-562 (1994).
40. + regulatory T cells cure murine colitis: the role of IL-10, TGF-β, and CTLA4. J. Immunol. 171, 5012-5017 (2003).
41. + immunoregulatory T cells that control autoimmune diabetes. Immunity 12, 431-440 (2000).
42. Hara, M. et al. IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J. Immunol. 166, 3789-3796 (2001).
43. + regulatory T cells prevent graft rejection: CTLA-4- and IL-10-dependent immunoregulation of alloresponses. J. Immunol. 166, 1080-1086 (2002).
44. + T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163, 5211-5218 (1999).
45. + regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur. J. Immunol. 32, 3267-3275 (2002).
46. H2 cells, Leishmania major infection, and colitis in mice. J. Immunol. 170, 394-399 (2003).
47. H2 cells. J. Immunol. 173, 267-274 (2004).
48. + HIV-specifc T cell immune responses in vitro and are associated with favorable clinical markers of disease status. J. Exp. Med. 200, 331-343 (2004).
49. + regulatory T cells control T-oell responses to human immunodeficiency virus and cytomegalovirus antigens. J. Virol. 78, 2454-2459 (2004).
50. Oswald-Richter, K. et al. HIV infection of naturally occurring and genetically reprogrammed human regulatory T-cells. PLoS Biol. 2, E198 (2004).
51. Hadeiba, H. & Locksley, R. M. Lung CD25 CD4 regulatory T cells suppress type 2 immune responses but not bronchial hyperreactivity. J. Immunol. 170, 5502-5510 (2003).
52. H2 cytokine production. J. Allergy Clin. Immunol. 111, 862-868 (2003).
53. H2 responses occurs in healthy, non-atopic individuals.
54. Regs: limiting collateral damage. J. Clin. Invest. 114, 1372-1378 (2004).
55. + T cells: a population of T cells with immune regulatory activities in vitro. Eur. J. Immunol. 28, 3435-3447 (1998).
56. + regulatory T cells and IL-10. J. Immunol. 171, 971-978 (2003).
57. Sundstedt, A. et al. Immunoregulatory role of IL-10 during superantigen-induced hyporesponsiveness in vivo. J. Immunol. 158, 180-186 (1997).
58. Sundstedt, A., O'Neill, E. J., Nicolson, K. S. & Wraith, D. C. Role for IL-10 in suppression mediated by peptide-induced regulatory T cells in vivo. J. Immunol. 170, 1240-1248 (2003).
59. + T-cell population, which inhibits antigen-specific T-cell responses. Nature 389, 737-742 (1997).
60. Levings, M. K. et al. IFN-α and IL-10 induce the differentiation of human type 1 T regulatory cells. J. Immunol. 166, 5530-5539 (2001).
61. Buer, J. et al. Interleukin 10 secretion and impaired effector function of major histocompatibility complex class II-restricted T cells anergized in vivo. J. Exp. Med. 187, 177-183 (1998).
62. H2 cytokines, which has implications for immunotherapy.
63. + regulatory T cells control the burst of superantigen-induced cytokine production: the role of IL-10. Int. Immunol. 14, 233-239 (2002).
64. H3 regulatory cells. Immunol. Rev. 182, 207-214 (2001).
65. + cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature 421, 388-392 (2003).
66. Bacchetta, R. et al. High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells. J. Exp. Med. 179, 493-502 (1994). This is an important early study that describes that high endogenous IL-10 production is a general phenomenon in patients with SCID in whom allogeneic haematopoietic stem-cell transplantation results in immunological reconstitution and induction of tolerance. This has been a seminal paper in the current resurgence of interest in the therapeutic applications of regulatory T cells.
67. + T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J. Exp. Med. 192, 1213-1222 (2000).
68. + T cell differentiation towards a phenotype win high IL-10 and reduced IL-4, IL-5 and IL-13 production. Eur. J. Immunol. 30, 2344-2354 (2000).
69. Miller, C., Ragheb, J. A. & Schwartz, R. H. Anergy and cytokine-mediated suppression as distinct superantigen-induced tolerance mechanisms in vivo. J. Exp. Med. 190, 53-64 (1999).
70. Reg cells, do not express FOXP3, but both populations nave a comparable ability to inhibit the proliferation of naive T cells.
71. Akdis, C. A., Blesken, T., Akdis, M., Wuthrich, B. & Blaser, K. Role of interleukin 10 in specific immunotherapy. J. Clin. Invest 102, 98-106 (1998). This is a comprehensive early study that shows the association of IL-10 production with tolerance to allergen. The authors provide evidence for EL-10 production in response to allergen following successful allergen immunotherapy of bee-keepers who had become tolerant following repeated stings and of non-atopic individuals.
72. Akbari, O., DeKruyff, R. H. & Umetsu, D. T. Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nature Immunol. 2, 725-731 (2001).
73. Akbari, O. et al. Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity. Nature Med. 8, 1024-1032 (2002). References 72 and 73 are studies from the same research group that identify pulmonary DCs and T cells as important sources of IL-10 in the lungs and identify the role of IL-10 in the induction of respiratory tolerance.
74. Boussiotis, V. A. et al. IL-10-producing T cells suppress immune responses in anergic tuberculosis patients. J. Clin. Invest. 105, 1317-1325 (2000).
75. + T cell clones producing both interferon-γ and interleukin-10 predominate in bronchoateolar lavages of active pulmonary tuberculosis patients. Clin. Immunol. 92, 224-234 (1999).
76. Trinchieri, G. Regulatory role of T cells producing both interferon γ and interleukin 10 in persistent infection. J. Exp. Med. 194, F53-F57 (2001).
77. + T regulatory cells suppress Helicobacter hepaticus-induced colitis. J. Exp. Med. 196, 505-515 (2002).
78. + T cell-mediated suppression by dendritic cells. Science 299, 1033-1036 (2003).
79. Akdis, M. et al. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J. Exp. Med. 199, 1567-1575 (2004). This is a recent study showing that IL-10-secreting regulatory T cells are the dominant cell subset that is specific for common environmental allergens in healthy individuals, whereas there is a high frequency of allergen-specific IL-4-secreting T cells in allergic individuals.
80. 3 and IL-10 can restore the reactivity of T cells from steroid-resistant patients to glucocorticoids and thereby induce IL-10 synthesis.
81. + T cells by grass pollen immunotherapy. J. Allergy Clin. Immunol. 111, 1255-1261 (2003).
82. Regs and allergic disease. J. Clin. Invest. 114, 1389-1397 (2004).
83. Bennett, C. L. et al. The immune dysregulation, potyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nature Genet. 27, 20-21 (2001).
84. Wildin, R. S. et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nature Genet. 27, 18-20 (2001).
85. Chatila, T. A. et al. JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome. J. Clin. Invest. 106, R75-R81 (2000). References 83-85 show that mutations in the human FOXP3 gene are associated with immune dysregulation and disease.
86. H2 cytokines by CD4CD25 regulatory T cells in birch allergies during birch pollen season. Clin. Exp. Allergy 34, 1364-1372 (2004).
87. + regulatory T cells in T helper 2 cell-mediated allergic inflammation in the airways. Am. J. Respr. Crit. Care Med. 164, 680-687 (2001).
88. H2 cell phenotype. J. Immunol. 172, 3842-3849 (2004).
89. Curotto de Lafaille, M. A. et al. Hyper immunoglobulin E response in mice with monoclonal populations of B and T lymphocytes. J. Exp. Med. 194, 1349-1359 (2001).
90. + T cells expressing membrane-bound TGF-β and FOXP3. J. Clin. Invest. 114, 28-38 (2004).
91. H1 clones. J. Exp. Med. 170, 2081-2095 (1989).
92. Moore, K. W., de Waal Malefyt, R., Coffman, R. L. & O'Garra, A. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19, 683-765 (2001). This is a comprehensive review of the biology of IL-10.
93. H1 cells. J. Immunol. 146, 3444-3451 (1991).
94. de Waal Malefyt, R. et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J. Exp. Med. 174, 915-924 (1991).
95. Gazzinelli, R. T., Oswald, I. P., James, S. L. & Sher, A. IL-10 inhibits parasite killing and nitrogen oxide production by IFN-γ-activated macrophages. J. Immunol. 148, 1792-1796 (1992).
96. Buelens, C. et al. Interleukin-10 prevents the generation of dendritic cells from human peripheral blood mononuclear cells cultured with interleukin-4 and granulocyte/macrophage-colony-stimulating factor. Eur. J. Immunol. 27, 756-762 (1997).
97. Gerber, J. S. & Mosser, D. M. Reversing lipopolysaccharide toxicity by ligating the macrophage Fcγ receptors. J. Immunol. 166, 6861-6868 (2001).
98. de Waal Malefyt, R., Abrams, J., Bennett, B., Figdor, C. G. & de Vries, J. E. Interleukin 10 (L-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J. Exp. Med. 174, 1209-1220 (1991).
99. Edwards, A. D. et al. Microbial recognition via Toll-like receptor-dependent and -independent pathways determines the cytokine response of murine dendritric cell subsets to CD40 triggering. J. Immunol. 169, 3652-3660 (2002).
100. McGuirk, P., McCann, C. & Mills, K. H. Pathogen-specific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: a novel strategy for evasion of protective T helper type 1 responses by Bordetella pertussis. J. Exp. Med. 195, 221-231 (2002).
101. H1, responses in vivo.
102. Asadullah, K. Sterry, W. & Volk, H. D. Interleukin-10 therapy - review of a new approach. Pharmacol. Rev. 55, 241-269 (2003). This is a comprehensive review of clinical studies involving IL-10.
103. Arock, M., Zuany-Amorim, C., Singer, M., Benhamou, M. & Pretolani, M. Interleukin-10 inhibits cytokine generation from mast cells. Eur. J. Immunol. 26, 166-70 (1996).
104. Royer, B. et al. Inhibition of IgE-induced activation of human mast cells by IL-10. Clin. Exp. Allergy 31, 694-704 (2001).
105. H1 responses.
106. Nouri-Aria, K. T. et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J. Immunol. 172, 3252-3259 (2004).
107. Jeannin, P., Lecoanet, S., Delneste, Y., Gauchat, J. F. & Bonnefoy, J. Y. IgE versus IgG4 production can be differentially regulated by IL-10. J. Immunol. 160, 3555-3561 (1998).
108. Borish, L. et al. Interleukin-10 regulation in normal subjects and patients with asthma. J. Allergy Clin. Immunol. 97, 1288-1296 (1996).
109. Lim, S., Crawley, E., Woo, P. & Barnes, P. J. Haplotype associated with low interleukin-10 production in patients with severe asthma. Lancet 352, 113 (1998).
110. Heaton, T. et al. An immunoepidemiological approach to asthma: identification of in-vitro T-cell response patterns associated with different wheezing phenotypes in children. Lancer 365, 142-149 (2005). References 108-110 provide evidence for an inverse correlation of IL-10 levels with disease severity.
111. Stampfli, M. R. et al. Interleukin-10 gene transfer to the airway regulates allergic mucosal sensitization in mice. Am. J. Respir. Cell Mol. Biol. 21, 586-596 (1999).
112. Oh, J. W. et al. CD4 T-helper cells engineered to produce IL-10 prevent allergen-induced airway hyperreactivity and inflammation. J. Alergy Clin. Immunol. 110, 460-468 (2002).
113. Fuchs, A. C. et al. Clinical, hematologic, and immunologic effects of interleukin-10 in humans. J. Clin. Immunol. 16, 291-303 (1996).
114. Norman, P. S. Immunotherapy: past and present. J. Allergy Clin. Immunol. 102, 1-10 (1998).
115. Bousquet, J. et al. Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American Academy of Allergy, Asthma and Immunology. Ann. Allergy Asthma Immunol. 81, 401-405 (1998).
116. Norman, P. S. Immunotherapy: 1999-2004. J. Allergy Clin. Immunol. 113, 1013-1023 (2004).
117. Wilson, D. R., Torres, L. I. & Durham, S. R. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst. Rev. 2, CD002893 (2003).
118. Moller, C. et al. Pollen immunotherapy reduces the development of asthma in children, with seasonal rhinoconjunctivitis (the PAT-study). J. Allergy Clin. Immunol. 109, 251-256 (2002).
119. Pajno, G. B., Barberio, G., DeLuca, F., Morabito, L. & Parmiani, S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin. Exp. Allergy 31, 1392-1397 (2001).
120. Casale, T. B. Status of immunotherapy: current and future. J. Allergy Clin. Immunol. 113, 1036-1039 (2004).
121. H1 phenotype.
122. H1 in T-cell clones specific for Phlp 1, a major grass pollen allergen. Clin. Exp. Allergy 27, 1007-1015 (1997).
123. H2 cytokine ratios. Immunology 105, 56-62 (2002).
124. Soderlund, A. et al. Allergen induced cytokine profiles in type I allergic individuals before and after immunotherapy. Immunol. Lett. 57, 177-181 (1997).
125. van Bever, H. P., Vereecke, I. F., Bridts, C. H., De Clerck, L. S. & Stevens, W. J. Comparison between the in vitro cytokine production of mononuclear cells of young asthmatics with and without immunotherapy (IT). Clin. Exp. Allergy 28, 943-949 (1998).
126. Klimek, L. et al. Short-term preseasonal birch pollen allergoid immunotherapy influences symptoms, specific nasal provocation and cytokine levels in nasal secretions, but not peripheral T-cell responses, in patients with allergic rhinitis. Clin. Exp. Allergy 29, 1326-1335 (1999).
127. Cook, D. N., Pisetsky, D. S. & Schwartz, D. A. Toll-like receptors in the pathogenesis of human disease. Nature Immunol. 5, 975-979 (2004).
128. H1 shift, and changes surface marker expression in venom-allergic subjects. Eur. J. Immunol. 27, 1131-1139 (1997).
129. Till, S. J., Francis, J. N., Nouri-Aria, K. & Durham, S. R. Mechanisms of immunotherapy. J. Allergy Clin. Immunol. 113, 1025-1034 (2004).
130. Jutel, M. et al. IL-10 and TGP-β cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur. J. Immunol. 33, 1205-1214 (2003).
131. Faith, A. et al. Impaired secretion of interleukin-4 and interleukin-13 by allergen-specific T cells correlates with defective nuclear expression of NR-AT2 and jun B: relevance to immunotherapy. Clin. Exp. Allergy 33, 1209-1215 (2003).
132. Oldfield, W. L., Larche, M. & Kay, A. B. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancer 360, 47-53 (2002).
133. Djurup, R. & Malling, H. J. High IgG4 antibody level is associated with failure of immunotherapy with inhalant allergens. Clin. Allergy 17, 459-468 (1987).
134. Ewan, P. W., Deighton, J., Wilson, A. B. & Lachmann, P. J. Venom-specific IgG antibodies in bee and wasp allergy: lack of correlation with protection from stings. Clin. Exp. Allergy 23, 647-660 (1993).
135. + human fetal B cells. J. Immunol. 148, 3398-3404 (1992).
136. 2-specific human IgE and IgG4 antibodies in vitro requires allergen-specific and nonspecific activation of T and B cells. J. Allergy Clin. Immunol. 99, 345-353 (1997). This is an early report of differential regulation of IgE and IgG4, which led to a series of publications (many of which are highlighted here) proposing that this is an important mechanism associated with successful allergen immunotherapy.
137. + T cells by inhibiting serum-IgE-facilitated allergen presentation. J. Immunol. 163, 2944-2952 (1999).
138. Wachholz, P. A. & Durham, S. R. Induction of 'blocking' IgG antibodies during immunotherapy. Clin. Exp. Allergy 33, 1171-1174 (2003).
139. Wachholz, P. A., Soni, N. K., Till, S. J. & Durham, S. R. Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J. Allergy Clin. Immunol. 112, 915-922 (2003).
140. Valenta, R. & Kraft, D. From allergen structure to new forms of allergen-specific immunotherapy. Curr. Opin. Immunol. 14, 718-727 (2002).
141. Kuehr, J. et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J. Allergy Clin. Immunol. 109, 274-280 (2002).
142. Rolinck-Weminghaus, C. et al. The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children. Allergy 59, 973-979 (2004).
143. Maurer, D. et al. The high affinity IgE receptor (FcεRi) mediates IgE-dependent allergen presentation. J. Immunol. 154, 6285-6290 (1995).
144. Novak, N., Bieber, T. & Katoh, N. Engagement of FcεRI on human monocytes induces the production of IL-10 and prevents their differentiation in dendritic cells. J. Immunol. 167, 797-804 (2001). References 143 and 144 provide evidence that crosslinking of IgE regulates APC function.
145. Larche, M. & Kay, A. B. Peptide therapy and asthma. Am. J. Respir. Crit. Care Med. 169, 1331-1332 (2004).
146. Norman, P. S. et al. Treatment of cat allergy with T-cell reactive peptides. Am. J. Respir. Crit. Care Med. 154, 1623-1628 (1996).
147. 2 induces specific T-cell anergy in patients allergic to bee venom. J. Allergy Clin. Immunol. 101, 747-754 (1998).
148. Haselden, B. M., Kay, A. B. & Larche, M. Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. J. Exp. Med. 189, 1885-1894 (1999). References 147 and 148 are independent studies that were the first to describe the successful use of peptides derived from allergen for use in allergen immunotherapy.
149. Oldfield, W. L., Kay, A. B. S. Larche, M. Allergen-derived T cell peptide-induced late asthmatic reactions precede the induction of antigen-specific hyporesponsiveness in atopic allergic asthmatic subjects. J. Immunol. 167, 1734-1739 (2001).
150. Ali, F. R., Oldfield, W. L., Higashi, N., Larche, M. & Kay A. B. Late asthmatic reactions induced by inhalation of allergen-derived T cell peptides. Am. J. Respir. Crit. Care Med. 169, 20-26 (2004).
151. Fellrath, J. M. et al. Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: results of a Phase I trial. J. Allergy Clin. Immunol. 111, 854-861 (2003).
152. Smith, T. R., Alexander, C., Kay, A. B., Larche, M. & Robinson, D. S. Cat allergen peptide immunotherapy reduces CD4 T cell responses to cat allergen but does not alter suppression by CD4 CD25 T cells: a double-blind placebo-controlled study. Allergy 59, 1097-1101 (2004).
153. Hoyne, G. F., O'Hehir, R. E., Wraith, D. C., Thomas, W. R. & Lamb, J. R. Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice. J. Exp. Med. 178, 1783-1788 (1993).
154. + T cells. J. Allergy Clin. Immunol. 113 (Suppl.), A333 (2004).
155. Krieg, A. M. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20, 709-760 (2002).
156. Akira, S. & Takeda, K. Toll-like receptor signalling. Nature Rev. Immunol. 4, 499-511 (2004).
157. Duramad, O. et al. IL-10 regulates plasmacytoid dendritic cell response to CpG-containing immunostimulatory sequences. Blood 102, 4487-4492 (2003).
158. Friedberg, J. W. et al. Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-α/β-induciblegene expression, without significant toxicity. Blood 105, 489-495 (2004).
159. Tighe, H. et al. Conjugation of immunostimulatory DNA to the short ragweed allergen Amb a 1 enhances its immunogenidty and reduces its allergenicity. J. Allergy Clin. Immunol. 106, 124-134 (2000).
160. H2 cytokine expression in PBMCs from human patients with ragweed allergy. J. Allergy Clin. Immunol. 108, 191-197 (2001).
161. Tulic, M. K. et al. Amb a 1-immunostimulatoryoligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J. Allergy Clin. Immunol. 113, 235-241 (2004).
162. Simons, F. E., Shikishima, Y., Van Nest, G., Eiden, J. J. & HayGlass, K. T. Selective immune redirection in humans with ragweed allergy by injecting
163. Durez, P. et al. Antiinflammatory properties of mycophenolate mofetil in murine endotoxemia: inhibition of TNF-α and upregulation of IL-10 release. Int. J. Immunopharmacol. 21, 581-587 (1999).
164. Durez, P. et al. In vivo induction of interteukin 10 by anti-CD3 monoclonal antibody or bacterial lipopolysaccharide: differential modulation by cyclosporin A. J. Exp. Med. 177, 551-555 (1993).
165. Bergmann, M. Sautner, T. Immunomodulatory effects of vasoactive catecholamines. Wien. Klin. Wochenschr. 114, 752-761 (2002).
166. Hasko, G., Deitch, E. A., Szabo, C., Nemeth, Z. H. & Vizi, E. S. Adenosine: a potential mediator of immunosuppression in multiple organ failure. Curr. Opin. Pharmacol. 2, 440-444 (2002).
167. Corral, L. G. et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α. J. Immunol. 163, 380-386 (1999).
168. H2-mediated airway inflammation by the sphingosine 1-phosphate receptor agonist FTY720. J. Immunol. 171, 6206-6214 (2003).
169. Schafer, P. H. et al. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-relatedimmunomodulatory drugs. J. Phamacol. Exp. Ther. 305, 1222-1232 (2003).
170. Casnici, C., Lattuada, D., Franco, P., Cattaneo, L. & Marelli, O. Regulation of human peripheral blood lymphocytes IL-10 by SMS 201-995. J. Neuroimmunol. 149, 210-216 (2004).
171. Wan, S., LeClerc, J. L. & Vincent, J. L. Cytokineresponses to cardiopulmonary bypass: lessons learned from cardiac transplantation. Ann. Thorac. Surg. 63, 269-276 (1997).
172. John, M. et al. Inhaled corticosteroids increase interteukin-10 but reduce macrophage inflammatory protein-1α, granulocyte-macrophage colony-stimulating factor and interferon-γ release from alveolar macrophages in asthma. Am. J. Respir. Crit. Care Med. 157, 256-262 (1998).
173. Hawrylowicz, C., Richards, D., Loke, T. K., Corrigan, C. & Lee, T. A defect in corticosteroid-induced IL-10 production in T lymphocytes from corticosteroid-resistant asthmatic patients. J. Allergy Clin. Immunol. 109, 369-370 (2002). This paper provides evidence that correlates failure to respond clinically to glucocorticoid treatment with a defect in T-cell responsiveness to glucocorticoids that results in reduced IL-10 expression in vitro.
174. H2 cytokine responses and enhances IL-10 responses. J. Allergy Clin. Immunol. 113 (Suppl.), A753 (2004).
175. Canning, M. O., Grotenhue, K., de Wit, H. J. &Drexhage, H. A. Opposing effects of dehydroepandrosterone and dexamethasone on the generation of monocyte-derived dendritic cells. Eur. J. Endocrinol. 143, 687-695 (2000).
176. Dong, X., Bachman, L. A., Kumar, R. & Griffin, M. D. Generation of antigen-specific, interleukin-10-producing T-cells using dendritic ceil stimulation and steroid hormone conditioning. Transpl. Immunol. 11, 323-333 (2003).
177. H2 paradigm in immunity to infectious diseases. Trends Immunol. 23, 450-455 (2002).
178. Zuany-Amorim, C. et al. Suppression of airway eosinophilia by killed Mycobacterium vaccae-induced allergen-specific regulatory T-cells. Nature Med. 8, 625-629 (2002).
179. Ulisse, S. et al. Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchrtis: effects of probiotic treatment. Am. J. Gastroenterol. 96, 2691-2699 (2001).
180. Kalliomaki, M., Salminen, S., Poussa, T., Arvilommi, H. & Isolauri, E. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lance 361, 1869-1871 (2003).
181. Kalliomaki, M. & Isolauri, E. Role of intestinal flora in the development of allergy. Curr. Opin. Allergy Clin. Immunol. 3, 15-20 (2003).
182. H2-specific response in vivo. J. Immunol. 165, 4848-4853 (2000).
183. + T helper cells engineered to produce latent TGF-β1 reverse allergen-induced airway hyperreactivity and inflammation. J. Clin. Invest. 105, 61-70 (2000).
184. Arkwright, P. D. & David, T. J. Effect of Mycobacterium vaccae on atopic dermatitis in children of different ages. Br. J. Dermatol. 149, 1029-1034 (2003).
185. Gorelik, L. & Flavell, R. A. Transforming growth factor-β in T-cell biology. Nature Rev. Immunol. 2, 46-53 (2002).
186. Tiemessen, M. M. et al. CD4 CD25 regulatory T cells are not functionally impaired in adult patients with IgE-mediated cow's milk allergy. J. Allergy Clin. Immunol. 110, 934-936 (2002).
187. Idzko, M. et al. Expression and function of histamine receptors in human monocyte-derived dendritic cells. J. Allergy Clin. Immunol. 109, 839-846 (2002).
188. H2 responses. FASEB J. 17, 1089-1095 (2003).